CD44 and neoplasm: Furthermore, the proportion of CD133+ tumor cells (CD133+Lin- cells) was significantly increased in tumors undergoing neoadjuvant chemotherapy compared with those without preoperative treatment (7.63% vs. 0.58%, P = 0.003; Figure 1C-D), as well as the proportion of CD44+CD24+Lin- cells (3.85% vs. 0.25%, P < 0.0001; Figure 1C, 1E).